98%
921
2 minutes
20
Rationale: Due to the numerous limitations of ketamine as a rapid-acting antidepressant drug (RAAD), research is still being conducted to find an effective and safe alternative to this drug. Recent studies indicate that the partial mGlu receptor negative allosteric modulator (NAM), 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine (M-5MPEP), has therapeutic potential as an antidepressant.
Objectives: The study aimed to investigate the potential rapid antidepressant-like effect of M-5MPEP in a mouse model of depression and to determine the mechanism of this action.
Methods: Chronic unpredictable mild stress (CUMS) was used as an animal model of depression. The effects of single and four-day administration of M-5MPEP on CUMS-induced animal behaviors reflecting anhedonia, apathy, and helplessness were studied. Western blot was applied to measure the levels of proteins potentially involved in a rapid antidepressant effect, including mammalian target of rapamycin (mTOR), eukaryotic elongation factor 2 (eEF2), tropomyosin receptor kinase B (TrkB), and serotonin transporter (SERT), both in the hippocampus and the prefrontal cortex (PFC). Furthermore, excitatory synaptic transmission and long-term potentiation (LTP) were measured in the medial PFC (mPFC).
Results: We showed that M-5MPEP administration for four consecutive days abolished CUMS-induced apathy- and anhedonia-like symptoms in a mouse model of depression. We also found that these effects were accompanied by changes in hippocampal TrkB levels and mTOR and eEF2 levels in the PFC. Using electrophysiological techniques, we showed that the four-day M-5MPEP treatment reversed chronic stress-induced increases in excitatory synaptic potential and CUMS-impaired LTP in the mPFC.
Conclusions: Partial mGlu receptor NAM, M-5MPEP, appears to be a potentially effective new RAAD and deserves further study.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084170 | PMC |
http://dx.doi.org/10.1007/s00213-024-06724-4 | DOI Listing |
Front Biosci (Landmark Ed)
August 2025
Department of Biomedical Sciences, University of Missouri-Kansas City, School of Medicine, Kansas City, MO 64108, USA.
Glutamate is an important neurotransmitter in the mammalian brain. Among the receptors that glutamate interacts with is metabotropic glutamate (mGlu) receptor 2, a Gα-coupled receptor. These receptors are primarily located on glutamatergic nerve terminals and act as presynaptic autoreceptors to produce feedback inhibition of glutamate release.
View Article and Find Full Text PDFMol Pharmacol
July 2025
Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New York. Electronic address:
Metabotropic glutamate receptors (mGlus) are obligate dimer G protein-coupled receptors that can all homodimerize and heterodimerize in select combinations. Responses of mGlu heterodimers to selective ligands, including orthosteric agonists and allosteric modulators, are largely unknown. The pharmacological properties of each group II and III mGlu homodimer (except the exclusively retinally expressed mGlu6) and several heterodimers were examined when stochastically assembled in HEK293T cells, or specifically measured using an improved G protein-mediated bioluminescence resonance energy transfer assay employing complemented fragments of Nanoluciferase.
View Article and Find Full Text PDFProtein Sci
September 2025
Faculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Metabotropic glutamate (mGlu) receptors play a crucial role in synaptic transmission through homodimeric or heterodimeric assemblies. Despite their dimeric nature, only one subunit within the mGlu dimer engages with G proteins during activation, and the biased activation can be further controlled by allosteric modulators. Considering the related molecular mechanisms remain elusive, we employed Gaussian accelerated molecular dynamics (GaMD) simulations to investigate the regulated mechanisms in mGlu-mGlu heterodimers.
View Article and Find Full Text PDFEur J Pharmacol
August 2025
Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, Canada; Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada; Division of Neurology, Department of Neurosciences, McGill University Health Centre, Montreal, QC, Canada. Electronic address: philippe.huot@
AZD8529 is a highly selective metabotropic glutamate 2 (mGlu) receptor positive allosteric modulator (PAM) that has undergone clinical trials for schizophrenia and smoking cessation. Previously, we demonstrated that the selective mGlu receptor PAMs LY-487,379, CBiPES, and biphenylindanone A (BINA) alleviated L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis-like behaviours (PLBs) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson's disease (PD). However, these drugs are not clinical candidates because of their pharmacological properties, contrary to AZD8529 which could be repurposed if pre-clinically efficacious.
View Article and Find Full Text PDFCell Rep
August 2025
Institute of Functional Genomics, University of Montpellier, CNRS, INSERM, 34094 Montpellier, France. Electronic address:
Cell surface G protein-coupled receptors (GPCRs) are tightly regulated through constitutive and agonist-induced internalization. While the mechanisms of constitutive internalization remain elusive, agonist-induced internalization very often involves receptor phosphorylation by GPCR kinases (GRKs) and β-arrestin recruitment. Dimeric class C metabotropic glutamate (mGlu1-mGlu8) receptors regulate synaptic transmission, but their internalization process remains ambiguous.
View Article and Find Full Text PDF